RxDoctor Payments Data

Kharia Holmes, MD

Internal Medicine · North Bethesda, MDNPI 1265668347

Payments from drug & device makers

$4,781in general payments, 2019–2025

Across 128 payments — averaging $37.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$890
  • AstraZeneca$879
  • Novo Nordisk$602
  • Harmony Biosciences LLC$477
  • Axsome Therapeutics, Inc.$308
  • Biohaven Pharmaceuticals, Inc.$232
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,781100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,781 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$143,147
Medicare patients
468
Services billed
2,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$24,599
EliquisApixaban12$17,039
SynthroidLevothyroxine Sodium30$2,336
Rosuvastatin Calcium57$1,764
Atorvastatin Calcium101$1,500
Metoprolol Succinate53$1,500
PaxlovidNirmatrelvir/Ritonavir16$1,336
Losartan Potassium54$1,060
Escitalopram Oxalate42$840
Ezetimibe19$827
Levothyroxine Sodium78$631
Amlodipine Besylate85$598
Pantoprazole Sodium28$519
Gabapentin24$429
Famotidine21$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$602$24,59915 claims
PfizerEliquis, Paxlovid$79$18,37428 claims
AbbVieSynthroid$890$2,33630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in North Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →